No Response to TNF Inhibitor in JIA? Another May Do the Trick

Registry study finds no advantage for switching to a different drug class

Related Keywords

United Kingdom ,John Gever ,Etanercept Enbrel ,Melissa Mannion ,University Of Alabama At Birmingham ,Arthritis Care Research ,Rheumatology Research Alliance ,Childhood Arthritis ,Arthritis Care ,Clinical Juvenile Arthritis Disease Activity ,Managing Editor ,Care Res ,